When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Systemic candidiasis

Last reviewed: 6 Aug 2025
Last updated: 23 Mar 2023

Summary

Definition

History and exam

Key diagnostic factors

  • fever
Full details

Other diagnostic factors

  • tachycardia
  • tachypnea
  • hypotension
  • poor capillary refill
  • acute mental confusion
  • decreased urine output
  • low oxygen saturation
  • rash
  • hepatosplenomegaly
  • hypothermia
Full details

Risk factors

  • use of central venous catheter
  • exposure to broad-spectrum antibiotics
  • hemodialysis
  • surgery
  • parenteral nutrition
  • immunosuppressants (e.g., chemotherapy, systemic corticosteroids, biologic and other immunosuppressants)
  • colonization at multiple sites
  • intravenous drug use
Full details

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • blood culture
  • CBC
  • ABG
  • lactate levels
  • coagulation studies
  • renal function tests
  • liver function test
  • serum glucose
Todos los datos

Pruebas diagnósticas que deben considerarse

  • 1,3-beta-D-glucan
  • T2 magnetic resonance assay
  • tissue biopsy
Todos los datos

Pruebas emergentes

  • polymerase chain reaction
  • matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry

Algoritmo de tratamiento

Inicial

suspected diagnosis

Agudo

confirmed diagnosis: non-neutropenic patients (no complications)

confirmed diagnosis: neutropenic patients (no complications)

confirmed diagnosis: with complications

Colaboradores

Autores

Brenda L. Tesini, MD

Assistant Professor

Infectious Diseases

Departments of Medicine and Pediatrics

University of Rochester Medical Center

Rochester

NY

Divulgaciones

BLT has received honoraria from Merck for educational contributions unrelated to this topic.

Agradecimientos

Dr Brenda L. Tesini would like to gratefully acknowledge Dr Jack D. Sobel and Dr Sanjay G. Revankar, previous contributors to this topic.

Divulgaciones

JDS declares that he has no competing interests. SR has received grants for research from Astellas, Gilead, and Merck, and has been involved in clinical trials for Cidara and Astellas.

Revisores por pares

John Fisher, MD

Professor of Medicine

Department of Medicine

Medical College of Georgia

Augusta

GA

Divulgaciones

JF is an author of a number of references cited in this topic. JF is a member of the speaker's bureau for the following companies: Pfizer, Merck, and Astellas.

Jean-Michel Livrozet, MD

Praticien hospitalier

Service de medecine de la Transplantation et d'Immunologie clinique

Hopital Edouard Herriot

Lyon

France

Divulgaciones

JML has been invited by Astellas, the manufacturer of micafungin, to attend a symposium, and invited by Gilead Sciences, manufacturer of liposomal amphotericin B, to attend different HIV conferences, and has been paid by Gilead Sciences for running HIV educational programs.

Matthew Falagas, MD, MSc, DSc

Director

Alfa Institute of Biomedical Sciences

Marousi

Athens

Greece

Divulgaciones

MF declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Tsay SV, Mu Y, Williams S, et al. Burden of candidemia in the United States, 2017. Clin Infect Dis. 2020 Dec 3;71(9):e449-53.Texto completo  Resumen

Centers for Disease Control and Prevention. ​Candida auris: information for laboratorians and health professionals. Jul 2021 [internet publication].Texto completo

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Bacterial sepsis
    • Drug-induced fever
    • Pulmonary embolism
    Más Diferenciales
  • Guías de práctica clínica

    • Revision and update of the consensus definitions of invasive fungal disease
    • Clinical practice guideline for the management of candidiasis
    Más Guías de práctica clínica
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad